R215
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 72
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.270
- XENOBIOTIC_METABOLISM+0.210
- APICAL_SURFACE+0.200
- COAGULATION+0.180
- DNA_REPAIR+0.100
- FATTY_ACID_METABOLISM+0.080
- BILE_ACID_METABOLISM+0.070
- P53_PATHWAY+0.070
- UV_RESPONSE_UP+0.070
- ESTROGEN_RESPONSE_LATE+0.060
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.360
- ANGIOGENESIS-0.300
- INTERFERON_GAMMA_RESPONSE-0.290
- G2M_CHECKPOINT-0.280
- MYC_TARGETS_V1-0.280
- UV_RESPONSE_DN-0.270
- HEDGEHOG_SIGNALING-0.250
- MTORC1_SIGNALING-0.230
- PROTEIN_SECRETION-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD001534_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.780 |
| 2 | MNG571 | — | — | 0.752 |
| 3 | MNG559 | — | — | 0.751 |
| 4 | SRR8613724 | — | F | 0.749 |
| 5 | TCGA-YF-AA3L-01A-11R-A38B-07 | — | — | 0.741 |
| 6 | TCGA-E2-A14U-01A-11R-A22K-07 | — | A | 0.737 |
| 7 | TCGA-AC-A3TN-01A-11R-A22K-07 | — | B | 0.735 |
| 8 | MNG656 | — | — | 0.728 |
| 9 | TCGA-CF-A3MH-01A-11R-A20F-07 | — | — | 0.727 |
| 10 | SRR13311177 | — | — | 0.726 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.270 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.070 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.060 | Idelalisib | — uncovered |
| MYOGENESIS | 0.060 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.050 | Inavolisib | — uncovered |
| APOPTOSIS | 0.050 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.040 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.020 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.010 | Remibrutinib | — uncovered |